CytRx Reveals Positive Results From Aldoxorubicin Preclinical Glioblastoma Study

(RTTNews) - CytRx Corp. (CYTR), a biopharmaceutical research and development company specializing in oncology, Thursday announced positive preclinical results from an in vivo study of aldoxorubicin in an animal model of glioblastoma. The company said the results support continued development of Aldoxorubicin as treatment for Relapsed Glioblastoma.

The company will present the results at the American Association for Cancer Research Annual Meeting being held April 5-9 in San Diego, CA.

CytRx announced data from the trial, which demonstrated that aldoxorubicin significantly increased survival almost 21/2 fold compared to doxorubicin treatment in an in vivo xenograft tumor model employing growth of human glioblastoma multiforme (GBM) tumors in mouse brains.

Aldoxorubicin combines chemotherapeutic agent doxorubicin with a novel single-molecule linker that binds directly and specifically to circulating albumin, the most plentiful protein in the bloodstream.

The company noted that Aldoxorubicin, but not doxorubicin, also demonstrated preferential accumulation and prolonged retention in the tumor tissue. These data, combined with aldoxorubicin's favorable safety profile, support the current evaluation of aldoxorubicin as a treatment for patients with GBM tumors.

Om Prakash, the study's principal investigator, and the poster presenter, said, "In addition to the clear survival benefit seen in the aldoxorubicin-treated animals, we also saw significant tumor regression and evidence of drug retention inside the tumors. Aldoxorubicin also significantly reduced the number of dividing cells within the tumors and showed a statistically relevant increased expression of apoptosis biomarkers."

CytRx is currently conducting a Phase 2 clinical trial evaluating aldoxorubicin in patients with late-stage GBM. CytRx also has initiated, under a special protocol assessment, a pivotal Phase 3 global trial with aldoxorubicin as a therapy for patients with soft tissue sarcomas.